JANX Stock — Janux Therapeutics Inc.: Cash, EV, Pipeline

Share price

$16.59

Market cap

$1,014.3M

Cash

$970.9M

Enterprise value

$43.4M

Balance sheet

Cash	$970.9M
Debt	$0.0M
Net cash	$970.9M
Enterprise value	$43.4M
Basic shares	61.1M shares
Fully diluted shares	74.2M shares
Fully diluted market cap	$1,231.0M
Cash per share	$15.89

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading JANX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 23, 2026	JANX008	Phase 1	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck	—
Nov 12 - Dec 24	JANX011	Early Phase 1	Autoimmune	—
Aug 12 - Sep 23	JANX007	Phase 1	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer	—
Jun 12 - Jul 24	JANX014	Phase 1	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration-resistant Prostate Cancer	—
Aug 12 - Sep 23	JANX013	Phase 1	Prostate Cancer; Castration-Resistant Prostate Cancer (CRPC); Metastatic Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

JANX007

Phase 1 · Active Modality: tumor-activated T cell engager (bispecific)

Target PSMA

Indications

Metastatic castration-resistant prostate cancer (mCRPC) (Phase 1)

Status note Lead candidate; PSMA-TRACTr. Phase 1a dose escalation complete; Phase 1b expansion ongoing in taxane-naive mCRPC, combination with darolutamide (AR pathway inhibitor), and post-PARP inhibitor populations.

JANX008

Phase 1 · Active Modality: tumor-activated T cell engager (bispecific)

Target EGFR

Indications

Multiple solid tumors (Phase 1)

Status note EGFR-TRACTr. First patient dosed Apr 2023; Phase 1a dose escalation complete; Phase 1a expansion cohorts in selected solid tumor indications initiated Dec 2025.

JANX014

Phase 1 · Active Modality: tumor-activated T cell engager (bispecific, double-masked)

Target PSMA

Indications

mCRPC (Phase 1)

Status note Double-masked PSMA-TRACTr; entered clinical evaluation Apr 2026.

JANX013

Preclinical · Active Modality: tumor-activated immunomodulator (bispecific, CD28 costimulatory)

Target PSMA / CD28

Indications

mCRPC (Preclinical)

Catalysts

— second half of 2026

Status note PSMA-targeted TRACIr incorporating CD28 costimulation; designed to pair with JANX007. Planned to enter clinical development 2H 2026.

JANX011

Phase 1 · Active Modality: bispecific T cell engager (ARM platform)

Target CD19

Indications

Autoimmune diseases (Phase 1)

Status note Lead CD19-ARM program; Phase 1 in healthy volunteers initiated Feb 2026. Being developed for autoimmune diseases.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	JANX007
Lead indication	Prostate Cancer
Lead phase	Phase 1
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05519449	Phase 1	Recruiting	Sponsor	Janux Therapeutics	—	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer	—
NCT07545811	Phase 1	Recruiting	Sponsor	Janux Therapeutics	—	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration-resistant Prostate Cancer	—
NCT07813637	Phase 1	Recruiting	Sponsor	Janux Therapeutics	—	Prostate Cancer; Castration-Resistant Prostate Cancer (CRPC); Metastatic Prostate Cancer	—
NCT05783622	Phase 1	Active, not recruiting	Sponsor	Janux Therapeutics	—	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck	—
NCT07291323	Early Phase 1	Recruiting	Sponsor	Janux Therapeutics	—	Autoimmune	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Janux Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	524,700	-458,900	0.15%	2026-08-14
ADAR1 Capital Management	420,881	+122,335	0.30%	2026-08-14
Logos Global Management	0	-1,000,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

JANX — Janux Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders